---
title: "Novogene: In the first three quarters of 2025, an asset impairment provision of 24.5321 million yuan was made"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262387230.md"
description: "Novogene announced that the company will hold a meeting on October 23, 2025, to review and approve the proposal for asset impairment provision. Based on the principle of prudence, the company assessed the relevant assets as of September 30, 2025, and the total impairment provision for this period is approximately RMB 24.5321 million, including credit impairment losses of RMB 24.3586 million and asset impairment losses of RMB 173,400. This will reduce the total pre-tax profit of the consolidated financial statements for the first three quarters of 2025 by RMB 24.5321 million, correspondingly reducing the owner's equity at the end of the reporting period. The data is unaudited and subject to the amount confirmed by the annual audit. Both the board of directors and the audit committee agreed to this provision"
datetime: "2025-10-23T09:12:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262387230.md)
  - [en](https://longbridge.com/en/news/262387230.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262387230.md)
generator: "portal-rs"
---

# Novogene: In the first three quarters of 2025, an asset impairment provision of 24.5321 million yuan was made

Novogene announced that the company will hold a meeting on October 23, 2025, to review and approve the proposal for asset impairment provision. Based on the principle of prudence, the company assessed the relevant assets as of September 30, 2025, and the total impairment provision for this period is approximately RMB 24.5321 million, including credit impairment losses of RMB 24.3586 million and asset impairment losses of RMB 173,400. This will reduce the total pre-tax profit in the consolidated financial statements for the first three quarters of 2025 by RMB 24.5321 million, correspondingly reducing the owner's equity at the end of the reporting period. The data is unaudited and subject to the amount confirmed by the annual audit. Both the board of directors and the audit committee agreed to this provision

### Related Stocks

- [688315.CN](https://longbridge.com/en/quote/688315.CN.md)

## Related News & Research

- [MultiversX: Supernova Network Release Goes Live on Mainnet - 10 Sep 2026](https://longbridge.com/en/news/298512370.md)
- [Cambridge Nutritional Sciences publishes 2026 annual report](https://longbridge.com/en/news/298269112.md)
- [Opus Genetics reports positive Phase 1/2 low-dose Cohort 1 data for OPGx-BEST1 gene therapy in BEST1 retinal disease](https://longbridge.com/en/news/298445913.md)
- [REG - 80 Mile PLC - R2.4 Proposed Merger with Greenland Energy Company](https://longbridge.com/en/news/298268427.md)
- [StenoCare flags uncertainty in Germany’s DKK 8.5 billion medical cannabis market under new reimbursement rules](https://longbridge.com/en/news/298219623.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**